Javascript must be enabled to continue!
CLINICAL EFFICACY OF ORAL AZITHROMYCIN VERSUS OTHER ANTIMICROBIAL DRUGS IN THE TREATMENT OF TYPHOID PATIENTS ACROSS ALL AGE GROUPS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
View through CrossRef
Background: Typhoid is a major health concern. Drug-resistant cases of typhoid have given rise to new debates. Azithromycin has shown adequate results. The study is designed to determine the clinical efficacy of oral azithromycin versus other antimicrobial drugs in typhoid patients. Method: The studies included in the systematic review are randomized controlled trials, comparing the clinical efficacy of azithromycin to other antimicrobial drugs on typhoid patients. We searched 1180 articles from Google Scholar, PubMed Central, Cochrane Library, PLOS ONE, and JSTOR on 16th October, 2023. The risk of bias was analyzed by visualizing the funnel plot, Begg's and Egger's test, and plotting risk of bias graphs. Forest plots are created to display the findings. Results: We identified 14 research articles (1556 participants). Odds ratios of the treatment outcomes were extracted. In a forest plot, the overall effect of the treatment outcome (CI=95%) of azithromycin, in comparison to fluoroquinolones appeared to be favourable (Random Effect Model (REM)=2.15, heterogeneity: I2=37%, τ2= 0.1729, p=0.15, the overall pooled effect was towards right side). Compared to chloramphenicol, azithromycin showed a high odds ratio (1.23). However, there was no difference in outcome among ceftriaxone and azithromycin groups (REM=0.67, heterogeneity: I2=0%, τ2=0%, p=0.78, the overall pooled effect touched the no-effect line). Conclusion: Azithromycin is more clinically efficacious than fluoroquinolones and chloramphenicol. The drug has fewer documented relapses in comparison with other antimicrobial drugs. Fever clearance time of azithromycin is greater than ceftriaxone and chloramphenicol.
Ayub Medical College, Abbottabad Pakistan
Title: CLINICAL EFFICACY OF ORAL AZITHROMYCIN VERSUS OTHER ANTIMICROBIAL DRUGS IN THE TREATMENT OF TYPHOID PATIENTS ACROSS ALL AGE GROUPS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
Description:
Background: Typhoid is a major health concern.
Drug-resistant cases of typhoid have given rise to new debates.
Azithromycin has shown adequate results.
The study is designed to determine the clinical efficacy of oral azithromycin versus other antimicrobial drugs in typhoid patients.
Method: The studies included in the systematic review are randomized controlled trials, comparing the clinical efficacy of azithromycin to other antimicrobial drugs on typhoid patients.
We searched 1180 articles from Google Scholar, PubMed Central, Cochrane Library, PLOS ONE, and JSTOR on 16th October, 2023.
The risk of bias was analyzed by visualizing the funnel plot, Begg's and Egger's test, and plotting risk of bias graphs.
Forest plots are created to display the findings.
Results: We identified 14 research articles (1556 participants).
Odds ratios of the treatment outcomes were extracted.
In a forest plot, the overall effect of the treatment outcome (CI=95%) of azithromycin, in comparison to fluoroquinolones appeared to be favourable (Random Effect Model (REM)=2.
15, heterogeneity: I2=37%, τ2= 0.
1729, p=0.
15, the overall pooled effect was towards right side).
Compared to chloramphenicol, azithromycin showed a high odds ratio (1.
23).
However, there was no difference in outcome among ceftriaxone and azithromycin groups (REM=0.
67, heterogeneity: I2=0%, τ2=0%, p=0.
78, the overall pooled effect touched the no-effect line).
Conclusion: Azithromycin is more clinically efficacious than fluoroquinolones and chloramphenicol.
The drug has fewer documented relapses in comparison with other antimicrobial drugs.
Fever clearance time of azithromycin is greater than ceftriaxone and chloramphenicol.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...

